Government of CanadaPublic Health Agency of Canada / Agency de la santé publique du Canada
   
Skip all navigation -accesskey z Skip to sidemenu -accesskey x Skip to main menu -accesskey m  
Français Contact Us Help Search Canada Site
PHAC Home Centres Publications Guidelines A-Z Index
Child Health Adult Health Seniors HealthSurveillance Health Canada
   
    Public Health Agency of Canada (PHAC)
Canada Communicable Disease Report

[Table of Contents]

  

Volume: 25S2 - June 1999

Hepatitis C - Prevention and Control: A Public Health Consensus

References

  1. Remis RS et al. Estimating the number of blood transfusion recipients infected by hepatitis C in Canada, 1960-85 and 1990-92. Report to Health Canada, June 22, 1998.

  2. LCDC. Prevention and control of hepatitis C: guidelines and recommendations. CCDR 1995;21S2:1-18.

  3. Canadian Paediatric Society. Vertical transmission of the hepatitis C virus: current knowledge and issues. Paediatrics and Child Health 1997;2(3):227-31.

  4. LCDC. Proceedings of the Consensus Conference on Infected Health Care Workers: risk for transmission of bloodborne pathogens. CCDR 1998;24S4:1-25.

  5. LCDC. An integrated protocol to manage health care workers exposed to bloodborne pathogens. CCDR 1997;23S2:1-14.

  6. National Task Force on HIV and Injection Drug Use. HIV, AIDS and injection drug use: a national action plan. Ottawa: Canadian Centre on Substance Abuse and the Canadian Public Health Association, May 1997.

Further Reading

Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitisC virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(RR19) [includes 158 references].

Chaudhary RK, Tepper M, ElSaadany S, GullyPR. Distribution of hepatitis C virus genotypes in Canada: results from the LCDC Sentinel Health Unit Surveillance System. Can J Infect Dis 1999;10:53-56i.

Garfein RS, Vlahov D, Galai N. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.

Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997;26(Suppl 1):43S-47S.

Lok ASF, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997;26(Suppl 1):48S-56S.

Poynard T, Marcellini P, Lee SS et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32i.

World Health Organization. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47i.

iPublished after this Consensus Conference but including information generally known at the Conference.

 

[Previous] [Table of Contents] [Next]

Last Updated: 2001-11-05 Top
Important Notices